/
LIDDS.ST
No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
LIDDS AB (publ)
LIDDS AB (publ), a pharmaceutical company headquartered in Uppsala, Sweden, specializes in the research, development, and marketing of therapeutic agents for cancer and various other medical conditions. The firm's innovative pipeline includes several drug candidates: NZ-2HOF is being advanced for prostate cancer; NZ-DTX targets a broad spectrum of malignancies such as breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX is in development for solid tumors; NZ-IO represents an immunotherapy; NZ-STING focuses on immuno-oncology; and NZ-TLR9 aims to bolster cancer immunotherapies. Additionally, LIDDS AB (publ) maintains a collaborative partnership with PharmIdea SIA, concentrating efforts on anti-cancer medications and the creation of sterile drug formulations.
www.liddspharma.com- Employees
- 1
- IPO / List date
- Jul 31, 2014
- HQ
- SE
Held by traders on TradeandTell
No one on the platform currently holds LIDDS.ST.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in LIDDS.ST as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LIDDS.ST yet.